Pharmaceuticals company Suven Life Sciences announced Q4FY24 & FY24 results: Financial Highlights: Suven Life Sciences reported a revenue of Rs 66.7 million in Q4FY24, showing a decline compared to the previous quarter's revenue of Rs 85.2 million. The company experienced a net loss after tax of Rs 265.4 million in Q4FY24, and a cumulative annual loss of Rs 1,050.8 million for the year FY24. Expenses Breakdown: R&D; and Operational expenses accounted for a significant portion of the total expenses, posting Rs 326.7 million for the quarter and Rs 1,397 million for the year. Depreciation and Amortisation costs were recorded at Rs 15.1 million for the quarter, while Finance costs were relatively low at Rs 0.3 million. Exceptional Items: An exceptional item included in the financials reflects an insurance claim received by the company, amounting to Rs 10.0 million. Comprehensive Income: The total comprehensive income for the quarter reflects a loss of Rs 267.4 million after factoring in other comprehensive income, which was a loss of Rs 2.0 million. Stock and Earnings per Share: The paid-up equity capital stood constant at Rs 218.1 million for the reported periods, while the Earnings Per Share (EPS) showed a loss of Rs 1.2 for the quarter and a loss of Rs 4.8 for the full year. Result PDF